<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To study the efficacy and safety of human leukocyte antigen (HLA) mismatched hematopoietic stem cell transplantation (HSCT) on severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: From January 2006 to May 2010, 17 patients received mismatched HSCT </plain></SENT>
<SENT sid="2" pm="."><plain>HLA antigens were 3-loci-mismatched in 9 patients, 2-loci-mismatched in 8 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received recombinant human granulocyte colony-stimulating factor (rhG-CSF) primed bone marrow cells plus peripheral blood stem cells after modified <z:chebi fb="0" ids="28901">busulfan</z:chebi>/<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> + antithymocyte immunoglobulin (BU/CY + ATG) conditioning regimen </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> patients achieved full donor type engraftment </plain></SENT>
<SENT sid="5" pm="."><plain>Grade III-IV <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) occurred in 3 patients and extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in 1 </plain></SENT>
<SENT sid="6" pm="."><plain>With a median following-up time of 285 (60 - 1670) d, 11 patients were alive, 9 of them had <z:mpath ids='MPATH_458'>normal</z:mpath> blood counts and the other 2 were blood transfusion independent </plain></SENT>
<SENT sid="7" pm="."><plain>Six patients died of transplant-related complications </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Mismatched HSCT is a feasible and safe option for SAA patients without sibling identical donors </plain></SENT>
</text></document>